| Chemohormonal therapy in metastatic hormone-sensitive prostate cancer CJ Sweeney, YH Chen, M Carducci, G Liu, DF Jarrard, M Eisenberger, ... New England Journal of Medicine 373 (8), 737-746, 2015 | 3147 | 2015 |
| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1439 | 2019 |
| Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile J Hrkach, D Von Hoff, MM Ali, E Andrianova, J Auer, T Campbell, ... Science translational medicine 4 (128), 128ra39-128ra39, 2012 | 1253 | 2012 |
| Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial CE Kyriakopoulos, YH Chen, MA Carducci, G Liu, DF Jarrard, NM Hahn, ... Journal of Clinical Oncology 36 (11), 1080-1087, 2018 | 1094 | 2018 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 897* | 2018 |
| Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study F Meric-Bernstam, H Hurwitz, KPS Raghav, RR McWilliams, M Fakih, ... The Lancet Oncology 20 (4), 518-530, 2019 | 562 | 2019 |
| Redefining the target: chemotherapeutics as antiangiogenics KD Miller, CJ Sweeney, GW Sledge Jr Journal of clinical oncology 19 (4), 1195-1206, 2001 | 547 | 2001 |
| Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial DC Smith, MR Smith, C Sweeney, AA Elfiky, C Logothetis, PG Corn, ... Journal of clinical oncology 31 (4), 412-419, 2013 | 533 | 2013 |
| An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells ML Guzman, RM Rossi, S Neelakantan, X Li, CA Corbett, DC Hassane, ... Blood, The Journal of the American Society of Hematology 110 (13), 4427-4435, 2007 | 526 | 2007 |
| Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of … CL Vale, S Burdett, LHM Rydzewska, L Albiges, NW Clarke, D Fisher, ... The lancet oncology 17 (2), 243-256, 2016 | 506 | 2016 |
| Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study JD Hainsworth, F Meric-Bernstam, C Swanton, H Hurwitz, DR Spigel, ... Journal of Clinical Oncology 36 (6), 536-542, 2018 | 486 | 2018 |
| Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ... Journal of Clinical Oncology 35 (27), 3097-3104, 2017 | 435 | 2017 |
| The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but … CJ Sweeney, KD Miller, SE Sissons, S Nozaki, DK Heilman, J Shen, ... Cancer research 61 (8), 3369-3372, 2001 | 430 | 2001 |
| Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation CL Hsieh, T Fei, Y Chen, T Li, Y Gao, X Wang, T Sun, CJ Sweeney, ... Proceedings of the National Academy of Sciences 111 (20), 7319-7324, 2014 | 418 | 2014 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 393 | 2015 |
| Cyclooxygenase-2 expression in human pancreatic adenocarcinomas MT Yip-Schneider, DS Barnard, SD Billings, L Cheng, DK Heilman, A Lin, ... Carcinogenesis 21 (2), 139-146, 2000 | 383 | 2000 |
| The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis A Pettersson, RE Graff, SR Bauer, MJ Pitt, RT Lis, EC Stack, NE Martin, ... Cancer epidemiology, biomarkers & prevention 21 (9), 1497-1509, 2012 | 374 | 2012 |
| Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis JH Hayes, DA Ollendorf, SD Pearson, MJ Barry, PW Kantoff, ST Stewart, ... Jama 304 (21), 2373-2380, 2010 | 341 | 2010 |
| Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study M Javle, MJ Borad, NS Azad, R Kurzrock, GK Abou-Alfa, B George, ... The lancet oncology 22 (9), 1290-1300, 2021 | 323 | 2021 |
| Outcome of patients with a performance status of 2 in eastern cooperative oncology group study E1594: a phase III trial in patients with metastatic nonsmall cell lung carcinoma CJ Sweeney, J Zhu, AB Sandler, J Schiller, CP Belani, C Langer, J Krook, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2001 | 314 | 2001 |
